Dahui Zhou
Princeton University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dahui Zhou.
Bioorganic & Medicinal Chemistry Letters | 2002
Richard Eric Mewshaw; Kristin Lynne Meagher; Ping Zhou; Dahui Zhou; Xiaojie Shi; Rosemary Scerni; Deborah H. Smith; Lee E. Schechter; Terrance H. Andree
The design and synthesis of a novel series of indole derivatives (9) having dual 5-HT transporter reuptake and 5-HT(1A) antagonist activity are described.
Journal of Medicinal Chemistry | 2008
Nicole T. Hatzenbuhler; Reinhardt Bernhard Baudy; Deborah Ann Evrard; Amedeo Arturo Failli; Boyd L. Harrison; Steven Edward Lenicek; Richard Eric Mewshaw; Annmarie Saab; Uresh Shantilal Shah; Jean Sze; Minsheng Zhang; Dahui Zhou; Michael Chlenov; Michael Z. Kagan; Jeannette Golembieski; Geoffrey Hornby; Margaret Lai; Deborah L. Smith; Kelly Sullivan; Lee E. Schechter; Terrance H. Andree
Novel compounds combining a 5-HT 1A moiety (3-aminochroman scaffold) and a 5-HT transporter (indole analogues) linked through a common basic nitrogen via an alkyl chain attached at the 1- or 3-position of the indole were evaluated for dual affinity at both the 5-HT reuptake site and the 5-HT 1A receptor. Compounds of most interest were found to have a 5-carbamoyl-8-fluoro-3-amino-3,4-dihydro-2 H-1-benzopyran linked to a 3-alkylindole (straight chain), more specifically substituted with a 5-fluoro (( R)-(-)- 35c), 5-cyano ((-)- 52a), or 5,7-difluoro ((-)- 52g). Several factors contributed to 5-HT 1A affinity, serotonin rat transporter affinity, and functional antagonism in vitro. Although most of our analogues showed good to excellent affinities at both targets, specific features such as cyclobutyl substitution on the basic nitrogen and stereochemistry at the 3-position of the chroman moiety seemed necessary for antagonism at the 5-HT 1A receptor. Branched linkers seemed to impart antagonism even as racemates; however, the potency of these analogues in the functional assay was not desirable enough to further pursue these compounds.
Bioorganic & Medicinal Chemistry | 2008
Dahui Zhou; Ping Zhou; Deborah A. Evrard; Kristin Lynne Meagher; Michael Byron Webb; Boyd L. Harrison; Donna M. Huryn; Jeannette Golembieski; Geoffrey Hornby; Lee E. Schechter; Deborah L. Smith; Terrance H. Andree; Richard Eric Mewshaw
Based on the previously reported discovery lead, 3-(cis-4-(4-(1H-indol-4-yl)piperazin-1-yl)cyclohexyl)-5-fluoro-1H-indole (2), a series of related arylpiperazin-4-yl-cyclohexyl indole analogs were synthesized then evaluated as 5-HT transporter inhibitors and 5-HT(1A) receptor antagonists. The investigation of the structure-activity relationships revealed the optimal pharmacophoric elements required for activities in this series. The best example from this study, 5-(piperazin-1-yl)quinoline analog (trans-20), exhibited equal binding affinities at 5-HT transporter (K(i)=4.9nM), 5-HT(1A) receptor (K(i)=6.2nM) and functioned as a 5-HT(1A) receptor antagonist.
Journal of Medicinal Chemistry | 2009
Dahui Zhou; Gary Paul Stack; Jennifer R. Lo; Amedeo Arturo Failli; Deborah Ann Evrard; Boyd L. Harrison; Nicole T. Hatzenbuhler; Megan Tran; Susan Christman Croce; Soo Yi; Jeannette Golembieski; Geoffrey Hornby; Margaret Lai; Qian Lin; Lee E. Schechter; Deborah L. Smith; Adam D. Shilling; Christine Huselton; Paul J. Mitchell; Chad E. Beyer; Terrance H. Andree
On the basis of the previously reported clinical candidate, SSA-426 (1), a series of related 2-piperazin-1-ylquinoline derivatives 3-16 were synthesized and evaluated as dual-acting serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists. In particular, compound 7 exhibits potent functional activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha1-adrenergic and dopaminergic receptors, acceptable pharmacokinetic properties, and a favorable in vivo profile.
Chirality | 2007
Oliver J. McConnell; Alvin C. Bach; Carl Balibar; Neal Byrne; Yanxuan Cai; Guy T. Carter; Michael Chlenov; Li Di; Kristi Fan; Igor Goljer; Yanan He; Don Herold; Michael Z. Kagan; Edward H. Kerns; Frank E. Koehn; Christina M. Kraml; Vasilios Marathias; Brian L. Marquez; Leonard A. McDonald; Lisa M. Nogle; Christopher Petucci; Gerhard Schlingmann; Gregory Tawa; Mark Tischler; R. Thomas Williamson; Alan G. Sutherland; William L. Watts; Mairead Young; Mei-Yi Zhang; Yingru Zhang
Journal of Medicinal Chemistry | 2004
Richard Eric Mewshaw; Dahui Zhou; Ping Zhou; Xiaojie Shi; Geoffrey Hornby; Taylor Spangler; Rosemary Scerni; Deborah F. Smith; Lee E. Schechter; Terrance H. Andree
Archive | 2006
Dahui Zhou; Gary Paul Stack; Jonathan Laird Gross; Hong Gao
Bioorganic & Medicinal Chemistry Letters | 2006
Dahui Zhou; Boyd L. Harrison; Uresh Shantilal Shah; Terrance H. Andree; Geoffrey Hornby; Rosemary Scerni; Lee E. Schechter; Deborah L. Smith; Kelly Sullivan; Richard Eric Mewshaw
Archive | 2000
Richard Eric Mewshaw; Ping Zhou; Dahui Zhou; Kristin Lynne Meagher; Magda Asselin; Deborah Ann Evrard; Adam M. Gilbert
Archive | 2006
Gavin David Heffernan; Gary Paul Stack; Jonathan Laird Gross; Dahui Zhou; Hong Gao